HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

BACKGROUND: Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced disease. It has previously been shown that HSP90 inhibitors act as radiosensitizers...

Descripción completa

Detalles Bibliográficos
Autores principales: McLaughlin, Martin, Barker, Holly E., Khan, Aadil A., Pedersen, Malin, Dillon, Magnus, Mansfield, David C., Patel, Radhika, Kyula, Joan N., Bhide, Shreerang A., Newbold, Kate L., Nutting, Christopher M., Harrington, Kevin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282703/
https://www.ncbi.nlm.nih.gov/pubmed/28143445
http://dx.doi.org/10.1186/s12885-017-3084-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282703/
https://www.ncbi.nlm.nih.gov/pubmed/28143445
http://dx.doi.org/10.1186/s12885-017-3084-0

Ejemplares similares